Synairgen plc (LON:SNG – Get Rating) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 16.80 ($0.20) and traded as low as GBX 10.26 ($0.12). Synairgen shares last traded at GBX 10.48 ($0.13), with a volume of 279,653 shares.
Synairgen Stock Performance
The company has a quick ratio of 6.35, a current ratio of 6.35 and a debt-to-equity ratio of 0.09. The stock has a market cap of £21.09 million, a price-to-earnings ratio of -74.82 and a beta of -2.20. The company has a 50 day simple moving average of GBX 13.10 and a 200 day simple moving average of GBX 16.76.
About Synairgen
(Get Rating)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
Further Reading
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
在周五的交易中,Synairgen plc(伦敦股票代码:SNG-GET Rating)的股价跌破了200日移动均线。该股的200日移动均线为16.80英镑(合0.20美元),交易价格低至10.26英镑(合0.12美元)。Synairgen的股票最后交易价格为10.48英镑(0.13美元),成交量为279,653股。
Synairgen股票表现
该公司的速动比率为6.35,流动比率为6.35,债务权益比为0.09。该股市值为2109万GB,市盈率为-74.82,贝塔系数为-2.20。该公司的50日简单移动均线切入位为13.10英镑,200日简单移动均线切入位为16.76英镑。
关于Synairgen
(获取评级)
Synairgen plc发现和开发治疗呼吸系统疾病的药物。该公司开发的产品有:治疗新冠肺炎的乙型吸入型干扰素SG001;治疗感冒和流感引起的哮喘的乙型干扰素吸入剂;治疗或预防慢性阻塞性肺病的乙型干扰素第二阶段临床试验;以及治疗特发性肺纤维化的LXL2抑制剂。
进一步阅读
- SVB金融崩溃对美国银行意味着什么
- 市场回顾周-3/6/3/10
- 2个近海钻探公司将大赚一笔
- 未来有望实现两位数上涨的三只史泰博股票
- 投资者能信任消费者来提升美国户外品牌吗?
接受Synairgen Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Synairgen和相关公司的最新新闻和分析师评级的每日简明摘要。